Biodistribution and excretion of radioactivity after the administration of 166Ho-chitosan complex (DW-166HC) into the prostate of rat

Abstract

The results of this study show clearly that most of the administered DW-166HC remained at the administration site. It is concluded that the chitosan complex may be used to retain 166Ho within a limited area in cancer of the prostate.

Radiochemical and biological evaluation of novel 153Sm/166Ho‐amino acid–chitosan complexes

“…In contrast, the labelling yield of 153 Sm/ 166 Ho-CHICO complexes was highly dependent on both parameters, reaching only 98% at pHC3 and using a 1% CHICO solution. 11,16 The stability of the CHICO-amino acid complexes was followed by ITLC, using the chromatographic systems indicated in the experimental section. Both complexes have in vitro radiochemical behaviour different than that of their CHICO analogous.…”

“…10 The main features of these complexes are their solubility under acidic conditions and the easy conversion to gel at the local of administration (physiological pH), with the corresponding retention of the radionuclide. Based on this principle, 153 Sm/ 166 Ho-chitosan complexes have been prepared with relatively high radiochemical purity (490%) and their biological behaviour has been considered promising for local therapy of prostate and skin cancer, [11][12][13] brain glioma, 14 renal cysts 15 and rheumatoid arthritis. [16][17] Following these results, 166 Ho-chitosan (DW-166HC) has been approved in Korea as a radiopharmaceutical for the treatment of small hepatocellular carcinoma (HCC).…”

Localized internal radiotherapy with 90Y particles embedded in a new thermosetting alginate gel: A feasibility study in pigs

“…Radiotherapy of tumours in the liver has been performed by selective injection into a hepatic artery of radioactive particles [6][7][8][9][10][11] or radioactive oil [12][13][14]. The formation of complexes with the gel-forming agent chitosan has enabled the retention of certain radionuclides in the knee joint [15,16], the prostate [17] or the liver [18].…”

Radiolabelled Nanoparticles for Diagnosis and Treatment of Cancer

“…Additional experiments tracking doxorubicin (DOX) fluorescence with DOX-loaded, folate-targeted liposomes (FTLs) indicate that liposomal DOX is rapidly internalized, released in the cytoplasmic compartment, and, shortly thereafter, detected in the nucleus, the entire process lasting 1-2 h. FR-mediated cell uptake of targeted liposomal DOX into a multidrug-resistant subline of M109-HiFR cells (M109R-HiFR) was unaffected by P-glycoprotein-mediated drug efflux. 122 …”

“…Thus, PAN may constitute a new approach to the achievement of maximal radioisotope efficiency with regard to intratumoral administration. 122 Noninvasive, focused hyperthermia can be achieved by using an externally applied alternating magnetic field (AMF) if effective concentrations of nanoparticles can be delivered to the target cancer cells. Monoclonal antibodies or peptides, linked to magnetic iron oxide nanoparticles (NP), represent a promising strategy to target cancer cells.…”